US FDA Approved Kite’s Viral Vector Manufacturing Facility to Produce Commercial Product
Kite, a Gilead Company, announced the retroviral vector (RVV) manufacturing facility of the company in California, has received the US Food and Drug Administration (FDA) approval for commercial production. Viral vectors are important components needed to manufactures cell therapies of Kite to treat certain types of blood cancers. Kite is the only cell therapy company […]
Continue Reading